DeepMed Research

RUTGERS, THE STATE UNIVERSITY

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Talimogene Laherparepvec and Panitumumab for the Treatment of Locally Advanced or Metastatic Squamous Cell Carcinoma of the Skin

Phase 1

Active, not recruiting

Conditions: Locally Advanced Skin Squamous Cell Carcinoma
Recurrent Skin Squamous Cell Carcinoma
Metastatic Skin Squamous Cell Carcinoma

Interventions: Biological: Panitumumab
Biological: Talimogene Laherparepvec

First Posted Date: 2019-11-15

Last Posted Date: 2024-06-14

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 5

Registration Number: NCT04163952

Locations: 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸
Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York, New York, United States
🇺🇸
New York University Langone Medical Center, New York, New York, United States

and more 2 locations

mHealth Mindfulness for Dementia Caregivers

Not Applicable

Completed

Conditions: Stress
Anxiety
Caregiver Burnout

Interventions: Behavioral: Mindfulness Coach

First Posted Date: 2019-11-04

Last Posted Date: 2021-09-05

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 60

Registration Number: NCT04150055

Locations: 🇺🇸
RWJ Barnabas, Monroe, New Jersey, United States
🇺🇸
RWJ Barnabas Monmouth South, Lakewood, New Jersey, United States

Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease

Phase 2

Completed

Conditions: Acute Myeloid Leukemia
Chronic Myelomonocytic Leukemia
Myeloblasts 10 Percent or More of Bone Marrow Nucleated Cells
Myelodysplastic Syndrome
Myeloproliferative Neoplasm
Recurrent Acute Myeloid Leukemia
Refractory Acute Myeloid Leukemia
Secondary Acute Myeloid Leukemia

Interventions: Drug: Azacitidine
Drug: Decitabine
Drug: Salsalate
Drug: Venetoclax

First Posted Date: 2019-10-31

Last Posted Date: 2023-05-24

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 5

Registration Number: NCT04146038

Locations: 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLC

Phase 1

Active, not recruiting

Conditions: Refractory Lung Non-Small Cell Carcinoma
Stage IV Lung Cancer AJCC v8

Interventions: Drug: Atezolizumab 1200 MG in 20 ML Injection
Radiation: Stereotactic Body Radiation Therapy
Drug: Varlilumab 3 mg/kg

First Posted Date: 2019-09-09

Last Posted Date: 2023-07-25

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 16

Registration Number: NCT04081688

Locations: 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

Feasibility of a Self-Management + Peer Mentoring Intervention for Adolescent and Young Adult Childhood Cancer Survivors

Not Applicable

Completed

Conditions: Childhood Cancer Survivors

First Posted Date: 2019-09-03

Last Posted Date: 2022-05-31

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 60

Registration Number: NCT04075734

Locations: 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

Propranolol for Challenging Behaviors in Autism

Phase 2

Active, not recruiting

Conditions: Autism Spectrum Disorder
Developmental Disability
Aggression
Self-Injurious Behavior
Challenging Behavior

Interventions: Drug: Propranolol

First Posted Date: 2019-08-06

Last Posted Date: 2024-02-07

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 6

Registration Number: NCT04047355

Locations: 🇺🇸
Department of Pediatrics, Division of Pediatric Neurology, Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States

Refinements of Functional Communication Training

Not Applicable

Recruiting

Conditions: Self-injurious Behavior
Aggression

Interventions: Behavioral: Trad FCT
Behavioral: Mult FCT
Behavioral: Mult FCT + Stimulus Fading

First Posted Date: 2019-08-05

Last Posted Date: 2024-04-09

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 24

Registration Number: NCT04045600

Locations: 🇺🇸
Children's Specialized Hospital - Rutgers University Center for Autism Research, Education, and Services, Somerset, New Jersey, United States

The Effect of Concord Grape Polyphenol-soy Protein Isolate Complex (GP-SPI) on Gut Microbiota

Not Applicable

Completed

Conditions: Mechanisms, Defense

Interventions: Dietary Supplement: GP-SPI

First Posted Date: 2019-07-12

Last Posted Date: 2023-11-18

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 34

Registration Number: NCT04018066

Locations: 🇺🇸
Rutgers, The State University of New Jersey, New Brunswick, New Jersey, United States

Utilizing Gaming Mechanics to Optimize Telerehabilitation Adherence in Persons With Stroke

Not Applicable

Completed

Conditions: Stroke

Interventions: Behavioral: Home Telerehabilitation using HoVRS

First Posted Date: 2019-06-14

Last Posted Date: 2023-07-10

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 32

Registration Number: NCT03985761

Locations: 🇺🇸
Rutgers The State University of New Jersey, Newark, New Jersey, United States

Heart Rate Variability Biofeedback for Smoking Cessation

Phase 2

Completed

Conditions: Tobacco Smoking

Interventions: Behavioral: Cognitive-Behavioral Smoking Cessation
Behavioral: Heart Rate Variability Biofeedback (HRVB)
Drug: Transdermal Nicotine patch

First Posted Date: 2019-06-03

Last Posted Date: 2020-08-25

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 10

Registration Number: NCT03972137

Locations: 🇺🇸
Rutgers, School of Arts and Sciences, One Spring Street, New Brunswick, New Jersey, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy